Celltrion, Inc., today announced that STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) has been added to ...

JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA ® (ustekinumab-stba), a biosimilar to STELARA ® (ustekinumab) has been added to the Costco Member ...

Samsung Biologics, Celltrion Lead Pharmaceutical Industry with Average Salary Over 100 Million Won Biopharmaceutical giants ...

Suh Jin-seok targets 700 billion won for Jimpenetra as shipments double Suh Jin-seok anticipates substantial growth for ...

The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, ...

On March 26, 2025, the FDA approved Fresenius Kabi’s denosumab biosimilars, CONEXXENCE® (denosumab-bnht) and BOMYNTRA® (denosumab-bnht), ...

Nextrade boosts stock offerings to include Samsung, SK Hynix Investors can trade large-cap stocks on Koreas first alternative ...

Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatment that modify the natural history of knee osteoarthritis, announces that it has been authorized by Health ...

The Kospi dropped 11.26 points, or 0.62 percent, to close at 2,615.81, as tech and shipyard stocks dropped heavily.

Trade volume was moderate at 359.99 million shares worth 6.84 trillion won ($4.7 billion) with decliners outpacing gainers ...

South Korea’s Celltrion has started work on a biosimilar version of pembrolizumab, Merck & Co’s blockbuster immunotherapy Keytruda. The PD-1 checkpoint inhibitor cancer treatment is fast ...